|
|
| |
|
 |
Press information 4 June 2008
“Follow-up research among patients consistently shows a marginal bone level reduction of just 0.4 mm or less for Astra Tech dental implants, a performance indicator at least three times superior to the industry norm. The findings involve hundreds of individual cases and are remarkable in their consistency,” says Lyndon Cooper, Professor of Dentistry in the Department of Prosthodontics at the University of North Carolina, who has performed one of the studies. |
 |
|
|
|
|
|
3M ESPE and Astra Tech AB, a leader and innovator in the dental implant industry, announce a global partnership to provide Astra Tech’s Atlantis™ patient-specific abutments to 3M ESPE Lava™ customers. The two companies have developed an interface which will enable the Lava™ Scan ST Design System to communicate directly with Astra Tech’s Atlantis technology. |
|
|
|
|
|
|
Press information May 2008.
Thousands of delegates from 23 countries are expected to attend the second Astra Tech World Congress, held June 4-7 at the newly opened Gaylord National Resort & Conference Center in Washington, DC. |
|
|
|
|
|
|
Press release, December 11, 2007
The Swedish medical device company Astra Tech, a subsidiary of AstraZeneca, continues expanding on the dental implant market by acquiring its Japanese distributor, Denics International Co. Ltd., with revenues of USD 30 million in 2006. |
|
|
|
|
|
|
Press release June 13, 2007
Astra Tech, a subsidiary of the pharmaceutical company AstraZeneca, is continuing its expansion in Mölndal, Sweden. On June 14, a new international research and training center will be officially opened. The investment totals SEK 220 million. Approximately 2,000 dentists from all over the world will come to the new center annually for training in the latest implant technology. In conjunction with the focus on research and training, close collaboration with the Institute of Odontology at the Sahlgrenska Academy will also be established. |
|
|
|
|
|
|
Press release September 21, 2005
New findings from clinical studies open the door to patients with a poor prognosis for implant treatment. The research by the medical device company Astra Tech reveals a remarkable 97% success rate in difficult cases, a finding that exceeds expectations.
“This is in line with my own experience,” says Wilfried Wagner, Professor and Head of the Clinic of Oral and Maxillofacial Surgery, University of Mainz. “The Astra Tech implant system offers great possibilities for treating patients with poor jawbone quality because it increases safety and predictability. When you are working at the margins this makes a big difference.” |
|
|
|
|
|
|
Medical device company Astra Tech AB, a subsidiary of AstraZeneca PLC, is acquiring Cresco Ti Systems from its primary owners SEB Företagsinvest, Credit Suisse Innoventure Capital AG, and Banque Cantonale Vaudoise. The deal represents less than one per cent of AstraZeneca’s net assets.
Cresco currently has around 30 per cent of the dental implant bridge market in Sweden. The company also has a strong position in central Europe.
“We expect to be able to multiply the Swedish success in other markets. The acquisition of Cresco means further expansion for Astra Tech in the market for dental implants. At present our growth rate is more than twice that of the global market”, said Peter Selley, President & CEO, Astra Tech AB.
|
|
|
|
|
|
|
|
|
|
|
|